RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00043197.xml
PDF herunterladen
CC BY-NC-ND 4.0 · Journal of Gastrointestinal and Abdominal Radiology 2020; 3(01): 053-063
DOI: 10.1055/s-0040-1708070
DOI: 10.1055/s-0040-1708070
Review Article
Imaging in Pancreatic Neuroendocrine Tumors
Abstract
Pancreatic neuroendocrine tumors (NETs) form a discrete subgroup of pancreatic neoplasms. They are rarer than pancreatic adenocarcinomas but need to be differentiated from other pancreatic tumors and pathologies as they carry a better prognosis. Imaging plays a central role in detecting, characterizing, and staging of pancreatic NETs as they tend to have typical radiological features. A lot of advancements have taken place in the field of imaging and theranostics which have revolutionized their detection and management. In this article we shall review the various imaging techniques available to the radiologist, salient imaging features of different types of pancreatic NETs, staging and grading systems, as well as a brief overview of their management.
Keywords
computed tomography - imaging - magnetic resonance imaging - neuroendocrine tumors - pancreas - pancreatic malignanciesPublikationsverlauf
Artikel online veröffentlicht:
29. April 2020
© .
Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India
-
References
- 1 Fraenkel M, Kim MK, Faggiano A, Valk GD. Epidemiology of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012; 26 (06) 691-703
- 2 Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011; 40 (01) 1-18,vii vii
- 3 Zhou J, Enewold L, Stojadinovic A. et al. Incidence rates of exocrine and endocrine pancreatic cancers in the United States. Cancer Causes Control 2010; 21 (06) 853-861
- 4 Exocrine and endocrine pancreas. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Manual of Clinical Microbiology. 7th ed.. New York, NY: Springer; 2010: 241-249
- 5 Exocrine and endocrine pancreas. In: Amin MB, Edge SB, Greene FL. et al. AJCC Cancer Staging Manual. 7th ed.. New York, NY: Springer; 2010: 241-249
- 6 Baur AD, Pavel M, Prasad V, Denecke T. Diagnostic imaging of pancreatic neuroendocrine neoplasms (pNEN): tumor detection, staging, prognosis, and response to treatment. Acta Radiol 2016; 57 (03) 260-270
- 7 Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008; 113 (07) Suppl 1807-1843
- 8 Kulke MH, Siu LL, Tepper JE. et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011; 29 (07) 934-943
- 9 Hilal T. Current understanding and approach to well differentiated lung neuroendocrine tumors: an update on classification and management. Ther Adv Med Oncol 2017; 9 (03) 189-199
- 10 Tamm EP, Bhosale P, Lee JH, Rohren EM. State-of-the-art imaging of pancreatic neuroendocrine tumors. Surg Oncol Clin N Am 2016; 25 (02) 375-400
- 11 Wang YW, Zhang XH, Wang BT. et al. Value of texture analysis of intravoxel incoherent motion parameters in differential diagnosis of pancreatic neuroendocrine tumor and pancreatic adenocarcinoma. Chin Med Sci J 2019; 34 (01) 1-9
- 12 Hwang EJ, Lee JM, Yoon JH. et al. Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size. Invest Radiol 2014; 49 (06) 396-402
- 13 Zhu L, Xue H, Sun H. et al. Insulinoma detection with MDCT: is there a role for whole-pancreas perfusion?. AJR Am J Roentgenol 2017; 208 (02) 306-314
- 14 Sundin A, Vullierme MP, Kaltsas G, Plöckinger U. Mallorca Consensus Conference participants, European Neuroendocrine Tumor Society. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology 2009; 90 (02) 167-183
- 15 Tan EH, Tan CH. Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol 2011; 2 (01) 28-43
- 16 Sahani DV, Bonaffini PA, Fernández-Del Castillo C, Blake MA. Gastroenteropancreatic neuroendocrine tumors: role of imaging in diagnosis and management. Radiology 2013; 266 (01) 38-61
- 17 Dogeas E, Chong CC, Weiss MJ, Ahuja N, Choti MA. Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis?. HPB (Oxford) 2018; 20 (03) 237-243
- 18 Fidler JL, Fletcher JG, Reading CC. et al. Preoperative detection of pancreatic insulinomas on multiphasic helical CT. AJR Am J Roentgenol 2003; 181 (03) 775-780
- 19 Gouya H, Vignaux O, Augui J. et al. CT, endoscopic sonography, and a combined protocol for preoperative evaluation of pancreatic insulinomas. AJR Am J Roentgenol 2003; 181 (04) 987-992
- 20 Lewis RB, Lattin Jr GE, Paal E. Pancreatic endocrine tumors: radiologic-clinicopathologic correlation. Radiographics 2010; 30 (06) 1445-1464
- 21 Rockall AG, Reznek RH. Imaging of neuroendocrine tumours (CT/MR/US). Best Pract Res Clin Endocrinol Metab 2007; 21 (01) 43-68
- 22 Lin XZ, Wu ZY, Tao R. et al. Dual energy spectral CT imaging of insulinoma-Value in preoperative diagnosis compared with conventional multi-detector CT. Eur J Radiol 2012; 81 (10) 2487-2494
- 23 Brenner R, Metens T, Bali M, Demetter P, Matos C. Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur J Radiol 2012; 81 (05) e746-e749
- 24 Jang KM, Kim SH, Song KD, Kim YK, Lee SJ, Choi D. Differentiation of solid-type serous cystic neoplasm from neuroendocrine tumour in the pancreas: value of abdominal MRI with diffusion-weighted imaging in comparison with MDCT. Clin Radiol 2015; 70 (02) 153-160
- 25 Kang BK, Kim JH, Byun JH. et al. Diffusion-weighted MRI: usefulness for differentiating intrapancreatic accessory spleen and small hypervascular neuroendocrine tumor of the pancreas. Acta Radiol 2014; 55 (10) 1157-1165
- 26 Jang KM, Kim SH, Min JH. et al. Value of diffusion-weighted MRI for differentiating malignant from benign intraductal papillary mucinous neoplasms of the pancreas. AJR Am J Roentgenol 2014; 203 (05) 992-1000
- 27 Guo C-G, Ren S, Chen X. et al. Pancreatic neuroendocrine tumor: prediction of the tumor grade using magnetic resonance imaging findings and texture analysis with 3-T magnetic resonance. Cancer Manag Res 2019; 11: 1933-1944
- 28 Guo C, Chen X, Xiao W, Wang Q, Sun K, Wang Z. Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1/2 tumors. OncoTargets Ther 2017; 10: 1465-1474
- 29 Tamm EP, Kim EE, Ng CS. Imaging of neuroendocrine tumors. Hematol Oncol Clin North Am 2007; 21 (03) 409-432,vii
- 30 Balachandran A, Bhosale PR, Charnsangavej C, Tamm EP. Imaging of pancreatic neoplasms. Surg Oncol Clin N Am 2014; 23 (04) 751-788
- 31 Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006; 36 (03) 228-247
- 32 Hofman MS, Lau WF, Hicks RJ. Somatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretation. Radiographics 2015; 35 (02) 500-516
- 33 Geijer H, Breimer LH. Somatostatin receptor PET/CT in neuroendocrine tumours: update on systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 2013; 40 (11) 1770-1780
- 34 Kauhanen S, Seppänen M, Minn H, Nuutila P. Clinical PET imaging of insulinoma and beta-cell hyperplasia. Curr Pharm Des 2010; 16 (14) 1550-1560
- 35 An L, Li W, Yao KC. et al. Assessment of contrast-enhanced ultrasonography in diagnosis and preoperative localization of insulinoma. Eur J Radiol 2011; 80 (03) 675-680
- 36 Ichikawa T, Peterson MS, Federle MP. et al. Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 2000; 216 (01) 163-171
- 37 Wang KX, Ben QW, Jin ZD. et al. Assessment of morbidity and mortality associated with EUS-guided FNA: a systematic review. Gastrointest Endosc 2011; 73 (02) 283-290
- 38 Hochwald SN, Zee S, Conlon KC. et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002; 20 (11) 2633-2642
- 39 Heller MT, Shah AB. Imaging of neuroendocrine tumors. Radiol Clin North Am 2011; 49 (03) 529-548,vii
- 40 Buetow PC, Miller DL, Parrino TV, Buck JL. Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization. Radiographics 1997; 17 (02) 453-472,quiz472A–472B
- 41 Ectors N. Pancreatic endocrine tumors: diagnostic pitfalls. Hepatogastroenterology 1999; 46 (26) 679-690
- 42 Mansour JC, Chen H. Pancreatic endocrine tumors. J Surg Res 2004; 120 (01) 139-161
- 43 Davies K, Conlon KC. Neuroendocrine tumors of the pancreas. Curr Gastroenterol Rep 2009; 11 (02) 119-127
- 44 Druce MR, Muthuppalaniappan VM, O’Leary B. et al. Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol 2010; 162 (05) 971-978
- 45 Prasad V, Sainz-Esteban A, Arsenic R. et al. Role of (68)Ga somatostatin receptor PET/CT in the detection of endogenous hyperinsulinaemic focus: an explorative study. Eur J Nucl Med Mol Imaging 2016; 43 (09) 1593-1600
- 46 Luo Y, Pan Q, Yao S. et al. Glucagon-like peptide-1 receptor PET/CT with 68Ga-NOTA-exendin-4 for detecting localized insulinoma: a prospective cohort study. J Nucl Med 2016; 57 (05) 715-720
- 47 Luo Y, Yao S, Li F. 68Ga-exendin-4 PET/CT is both sensitive and specific in diagnosing insulinomas. J Nucl Med 2017; 58 supplement 1 237
- 48 Naswa N, Sharma P, Kumar A. et al. Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. AJR Am J Roentgenol 2011; 197 (05) 1221-1228
- 49 Brown CK, Bartlett DL, Doppman JL. et al. Intraarterial calcium stimulation and intraoperative ultrasonography in the localization and resection of insulinomas. Surgery 1997; 122 (06) 1189-1193,discussion1193–1194
- 50 Horton KM, Hruban RH, Yeo C, Fishman EK. Multi-detector row CT of pancreatic islet cell tumors. Radiographics 2006; 26 (02) 453-464
- 51 Gullo L, Migliori M, Falconi M. et al. Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 2003; 98 (11) 2435-2439
- 52 Balachandran A, Tamm EP, Bhosale PR. et al. Venous tumor thrombus in nonfunctional pancreatic neuroendocrine tumors. AJR Am J Roentgenol 2012; 199 (03) 602-608
- 53 Klimstra DS, Kloppell G, La RosaS, Rindi G. Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours: Digestive System Tumours. 5th ed.. Lyon, France: WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer; 2019: 16
- 54 Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010; 16 (03) 978-985
- 55 Cappelli C, Boggi U, Mazzeo S. et al. Contrast enhancement pattern on multidetector CT predicts malignancy in pancreatic endocrine tumours. Eur Radiol 2015; 25 (03) 751-759
- 56 Luo Y, Dong Z, Chen J. et al. Pancreatic neuroendocrine tumours: correlation between MSCT features and pathological classification. Eur Radiol 2014; 24 (11) 2945-2952
- 57 Takumi K, Fukukura Y, Higashi M. et al. Pancreatic neuroendocrine tumors: correlation between the contrast-enhanced computed tomography features and the pathological tumor grade. Eur J Radiol 2015; 84 (08) 1436-1443
- 58 Bergsland EKWE, Rindo G. Neuroendocrine tumors of the pancreas. In: Amin MB. AJCC Cancer Staging Manual. 8th ed.. Chicago, IL: American Joint Committee on Cancer; 2017: 407
- 59 Kazanjian KK, Reber HA, Hines OJ. Resection of pancreatic neuroendocrine tumors: results of 70 cases. Arch Surg 2006; 141 (08) 765-769,discussion769–770
- 60 Phan GQ, Yeo CJ, Hruban RH, Littemoe KD, Pitt HA, Cameron JL. Surgical experience with pancreatic and peripancreatic neuroendocrine tumors: review of 125 patients. J Gastrointest Surg 1998; 2 (05) 473-482
- 61 Sarmiento JM, Que FG. Hepatic surgery for metastases from neuroendocrine tumors. Surg Oncol Clin N Am 2003; 12 (01) 231-242
- 62 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
- 63 King J, Quinn R, Glenn DM. et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008; 113 (05) 921-929
- 64 Siperstein AE, Berber E. Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases. World J Surg 2001; 25 (06) 693-696
- 65 Bushnell Jr DL, O’Dorisio TM, O’Dorisio MS. et al. 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol 2010; 28 (10) 1652-1659
- 66 Teunissen JJ, Kwekkeboom DJ, de Jong M, Esser JP, Valkema R, Krenning EP. Endocrine tumours of the gastrointestinal tract. Peptide receptor radionuclide therapy. Best Pract Res Clin Gastroenterol 2005; 19 (04) 595-616